VALIDATION OF AN ALGORITHM TO IDENTIFY HR+/HER2-METASTATIC BREAST CANCER IN CLAIMS DATA

被引：0
作者：
Chin, A. [1 ]
Ip, Q. [1 ]
Wu, X. [1 ]
Lyle, D. [2 ]
机构：
[1] Komodo Hlth, San Francisco, CA USA
[2] NeoGenomics, Ft Myers, FL USA
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EPH56
引用
收藏
页码：S163 / S163
页数：1
相关论文
共 50 条
  • [41] nextMONARCH: Final overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with HR+, HER2-metastatic breast cancer
    Hamilton, E. P.
    Cortes, J.
    Ozyilkan, O.
    Chen, S-C.
    Petrakova, K.
    Manikhas, A.
    Jerusalem, G.
    Hegg, R.
    Huober, J.
    Chapman, S. C.
    Yang, Z.
    Chen, Y.
    Johnston, E. L.
    Martin, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S348 - S348
  • [42] PIK3CA Mutation Assessment in HR+/HER2-Metastatic Breast Cancer: Overview for Oncology Clinical Practice
    Criscitiello, Carmen
    Marra, Antonio
    Curigliano, Giuseppe
    JOURNAL OF MOLECULAR PATHOLOGY, 2021, 2 (01): : 42 - 54
  • [43] Real-world palbociclib dosing patterns and implications for drug costs in the treatment of HR+/HER2-metastatic breast cancer
    Li, Nanxin
    Du, Ella X.
    Chu, Lihao
    Peeples, Miranda
    Xie, Jipan
    Barghout, Victoria
    Tang, Derek H.
    EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (12) : 1167 - 1178
  • [44] Treatment patterns and resource utilization among patients with HR+/HER2-metastatic breast cancer in a privately insured US population
    Goyal, R. K.
    Carter, G. C.
    Nagar, S. N.
    Smyth, E. N.
    Price, G. L.
    Huang, Y-J
    Bromund, J. L.
    Li, L.
    Schilder, J. M.
    Davis, K. L.
    Kaye, J. A.
    CANCER RESEARCH, 2017, 77
  • [45] Abemaciclib for treating patients with HR+/HER2-metastatic breast cancer: a real-world study in France, Italy and Spain
    Blancas, Isabel
    Grosjean, Jessica
    Pedersini, Rebecca
    Buzzoni, Carlotta
    Sleilaty, Ghassan
    Molero, Alberto
    Tamma, Antonella
    Chouaki, Nadia
    Atienza, Manuel
    Emde, Anna
    Siddi, Sara
    Bayona, Rodrigo Sanchez
    Del Mastro, Lucia
    Fakhouri, Walid
    FUTURE ONCOLOGY, 2024, 20 (31) : 2371 - 2384
  • [46] Economic impact of longer treatment duration in first-line for HR+/HER2-metastatic breast cancer: A retrospective analysis
    Abbass, Ibrahim M.
    Ng, Carmen
    Dillon, Allison
    Cheng, Anna
    Du Toit, Yolande
    Basho, Reva K.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [47] A Systematic Review of the Prevalence and Diagnostic Workup of PIK3CA Mutations in HR+/HER2-Metastatic Breast Cancer
    Anderson, Elizabeth J.
    Mollon, Lea E.
    Dean, Joni L.
    Warholak, Terri L.
    Aizer, Ayal
    Platt, Emma A.
    Tang, Derek H.
    Davis, Lisa E.
    INTERNATIONAL JOURNAL OF BREAST CANCER, 2020, 2020
  • [48] Multiomic advanced diagnostics for CDK 4/6 drug target activation mapping of HR+/HER2-metastatic breast cancer
    Abu-Khalaf, Maysa M.
    Hatzis, Christos
    Hodge, K. Alex
    Valdes, Frances
    Sikov, William
    Mita, Monica
    Denduluri, Neelima
    Awerkamp, Kris
    Murphy, Rita
    Zelterman, Daniel
    Dunetz, Bryant
    Petricoin, Emanuel
    Pierobon, Mariaelena
    CANCER RESEARCH, 2021, 81 (04)
  • [49] A Phase 2 Study of Abemaciclib in Patients (PTS) with Brain Metastases (BM) Secondary to HR+, HER2-Metastatic Breast Cancer (MBC)
    Anders, Carey
    Le Rhun, Emily
    Bachelot, Thomas
    Yardley, Denise
    Awade, Ahmad
    Conte, Pierre Franco
    Cabos, Peter
    Bear, Melissa
    Tolaney, Sarah
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 10 - 10
  • [50] COMPARATIVE EFFECTIVENESS OF EVEROLIMUS VS. FULVESTRANT MONOTHERAPY AMONG POSTMENOPAUSAL WOMEN WITH HR+/HER2-METASTATIC BREAST CANCER
    Lin, P. L.
    Hao, Y.
    Xie, J.
    Li, N.
    Ohashi, E.
    Koo, V
    Wu, E. Q.
    VALUE IN HEALTH, 2015, 18 (03) : A192 - A192
12345